If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEMATOLOGY<br /> ISSN 2053-6631 Vol 3.1 • July 2015 • emjreviews.com<br /> INSIDE<br /> Review of<br /> EHA 2015<br /> Vienna, Austria<br /> CONTENTS<br /> EDITORIAL BOARD......................................................................................................................................... 4<br /> CONGRESS REVIEW........................................................................................................................................ 12<br /> • Review of the 20th Congress of the European Hematology Association held in<br /> Vienna, Austria, 11th-14th June 2015<br /> INTERVIEWS WITH EMJ HEMATOLOGY EDITORIAL BOARD AND AUTHORS................................. 28<br /> • Viola Popov<br /> • Emanuele Angelucci<br /> • Sophia Delicou<br /> • Felipe Prósper<br /> • Eloísa Urrechaga<br /> • Anna Rita Migliaccio<br /> SYMPOSIUM <a title="EMJ Hematology 3.1 2015 page 1" href="http://viewer.zmags.com/publication/bc55dcab?page=1"> HEMATOLOGY ISSN 2053-6631 </a> <a title="EMJ Hematology 3.1 2015 page 2" href="http://viewer.zmags.com/publication/bc55dcab?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Hematology 3.1 2015 page 3" href="http://viewer.zmags.com/publication/bc55dcab?page=3"> HEMATOLOGY • PERSPECTIVES ON THE TREATMENT OF M</a> <a title="EMJ Hematology 3.1 2015 page 4" href="http://viewer.zmags.com/publication/bc55dcab?page=4"> Editorial Board Editor-in-Chief: Prof Emili Mo</a> <a title="EMJ Hematology 3.1 2015 page 5" href="http://viewer.zmags.com/publication/bc55dcab?page=5"> Hematology Prof Rudiger Helhmann, Chairman, E</a> <a title="EMJ Hematology 3.1 2015 page 6" href="http://viewer.zmags.com/publication/bc55dcab?page=6"> Ph+ CML Bosulif® (bosutinib): In the sea of choi</a> <a title="EMJ Hematology 3.1 2015 page 7" href="http://viewer.zmags.com/publication/bc55dcab?page=7"> European Medical Journal EMJ Hematology Vol 3.1</a> <a title="EMJ Hematology 3.1 2015 page 8" href="http://viewer.zmags.com/publication/bc55dcab?page=8"> Gaucher Disease The most common of a family of ra</a> <a title="EMJ Hematology 3.1 2015 page 9" href="http://viewer.zmags.com/publication/bc55dcab?page=9"> Welcome Hello and a very warm welcome to the n</a> <a title="EMJ Hematology 3.1 2015 page 10" href="http://viewer.zmags.com/publication/bc55dcab?page=10"> 18th ECCO - 40th ESMO E</a> <a title="EMJ Hematology 3.1 2015 page 11" href="http://viewer.zmags.com/publication/bc55dcab?page=11"> Foreword </a> <a title="EMJ Hematology 3.1 2015 page 12" href="http://viewer.zmags.com/publication/bc55dcab?page=12"> EHA ANNUAL CONGRESS 2015 MESSE CONFERENCE CENTRE</a> <a title="EMJ Hematology 3.1 2015 page 13" href="http://viewer.zmags.com/publication/bc55dcab?page=13"> Welcome to the European Medical Journal review of</a> <a title="EMJ Hematology 3.1 2015 page 14" href="http://viewer.zmags.com/publication/bc55dcab?page=14"> EHA ANNUAL CONGRESS 2015 EHA’s board this </a> <a title="EMJ Hematology 3.1 2015 page 15" href="http://viewer.zmags.com/publication/bc55dcab?page=15"> H IGHLIGHTS Kinase Inhibitor Activit</a> <a title="EMJ Hematology 3.1 2015 page 16" href="http://viewer.zmags.com/publication/bc55dcab?page=16"> EHA ANNUAL CONGRESS 2015 leukaemia (AML) were </a> <a title="EMJ Hematology 3.1 2015 page 17" href="http://viewer.zmags.com/publication/bc55dcab?page=17"> created a mouse model by mutation of the DNMT3A</a> <a title="EMJ Hematology 3.1 2015 page 18" href="http://viewer.zmags.com/publication/bc55dcab?page=18"> EHA ANNUAL CONGRESS 2015 </a> <a title="EMJ Hematology 3.1 2015 page 19" href="http://viewer.zmags.com/publication/bc55dcab?page=19"> newly diagnosed CML patients in 20 Eur</a> <a title="EMJ Hematology 3.1 2015 page 20" href="http://viewer.zmags.com/publication/bc55dcab?page=20"> EHA ANNUAL CONGRESS 2015 (41%) achieved a comple</a> <a title="EMJ Hematology 3.1 2015 page 21" href="http://viewer.zmags.com/publication/bc55dcab?page=21"> The results indicate that MM is less likely to wo</a> <a title="EMJ Hematology 3.1 2015 page 22" href="http://viewer.zmags.com/publication/bc55dcab?page=22"> EHA ANNUAL CONGRESS 2015 BTZ i</a> <a title="EMJ Hematology 3.1 2015 page 23" href="http://viewer.zmags.com/publication/bc55dcab?page=23"> PERSIST-1 was set up in to compare the efficacy a</a> <a title="EMJ Hematology 3.1 2015 page 24" href="http://viewer.zmags.com/publication/bc55dcab?page=24"> EHA ANNUAL CONGRESS 2015 The Congress GFI1B that </a> <a title="EMJ Hematology 3.1 2015 page 25" href="http://viewer.zmags.com/publication/bc55dcab?page=25"> transporter, ferroportin, significantly expres</a> <a title="EMJ Hematology 3.1 2015 page 26" href="http://viewer.zmags.com/publication/bc55dcab?page=26"> EHA ANNUAL CONGRESS 2015 The research team, led </a> <a title="EMJ Hematology 3.1 2015 page 27" href="http://viewer.zmags.com/publication/bc55dcab?page=27"> Sharing expertise haematology .com /S</a> <a title="EMJ Hematology 3.1 2015 page 28" href="http://viewer.zmags.com/publication/bc55dcab?page=28"> INTERVIEWS </a> <a title="EMJ Hematology 3.1 2015 page 29" href="http://viewer.zmags.com/publication/bc55dcab?page=29"> A: EHA and ASH congresses give us a lot of new in</a> <a title="EMJ Hematology 3.1 2015 page 30" href="http://viewer.zmags.com/publication/bc55dcab?page=30"> INTERVIEWS “Blood diseases must be considered in </a> <a title="EMJ Hematology 3.1 2015 page 31" href="http://viewer.zmags.com/publication/bc55dcab?page=31"> cell disease, and have found that the use </a> <a title="EMJ Hematology 3.1 2015 page 32" href="http://viewer.zmags.com/publication/bc55dcab?page=32"> INTERVIEWS </a> <a title="EMJ Hematology 3.1 2015 page 33" href="http://viewer.zmags.com/publication/bc55dcab?page=33"> A: To improve the percentage of patients that we </a> <a title="EMJ Hematology 3.1 2015 page 34" href="http://viewer.zmags.com/publication/bc55dcab?page=34"> INTERVIEWS Q: Last year you co-authored a paper </a> <a title="EMJ Hematology 3.1 2015 page 35" href="http://viewer.zmags.com/publication/bc55dcab?page=35"> I became Professor of Medicine at Mount Sinai by </a> <a title="EMJ Hematology 3.1 2015 page 36" href="http://viewer.zmags.com/publication/bc55dcab?page=36"> INTERVIEWS the discovery of erythropoietin</a> <a title="EMJ Hematology 3.1 2015 page 37" href="http://viewer.zmags.com/publication/bc55dcab?page=37"> Would you like to write for the EMJ blog? Interac</a> <a title="EMJ Hematology 3.1 2015 page 38" href="http://viewer.zmags.com/publication/bc55dcab?page=38"> THROMBOSIS IN HAEMATOLOGICAL DISORDERS: </a> <a title="EMJ Hematology 3.1 2015 page 39" href="http://viewer.zmags.com/publication/bc55dcab?page=39"> previous history of thrombosis, etc.), tumou</a> <a title="EMJ Hematology 3.1 2015 page 40" href="http://viewer.zmags.com/publication/bc55dcab?page=40"> MPNs such as essential thrombocythaemia (ET)</a> <a title="EMJ Hematology 3.1 2015 page 41" href="http://viewer.zmags.com/publication/bc55dcab?page=41"> damage, surgery, or pregnancy. The alternati</a> <a title="EMJ Hematology 3.1 2015 page 42" href="http://viewer.zmags.com/publication/bc55dcab?page=42"> FXIIa FVaActivated protein C - protei</a> <a title="EMJ Hematology 3.1 2015 page 43" href="http://viewer.zmags.com/publication/bc55dcab?page=43"> develop the PIGA mutation, leading to </a> <a title="EMJ Hematology 3.1 2015 page 44" href="http://viewer.zmags.com/publication/bc55dcab?page=44"> Thrombotic event rate (per 100 patient-years) 12</a> <a title="EMJ Hematology 3.1 2015 page 45" href="http://viewer.zmags.com/publication/bc55dcab?page=45"> among patients with malignancy versus those witho</a> <a title="EMJ Hematology 3.1 2015 page 46" href="http://viewer.zmags.com/publication/bc55dcab?page=46"> 49. Weitz IC. Thrombosis in Paroxysmal Nocturnal </a> <a title="EMJ Hematology 3.1 2015 page 47" href="http://viewer.zmags.com/publication/bc55dcab?page=47"> WHY BIOSIMILARS MATTER: AN INNOVATIVE SOLUTION</a> <a title="EMJ Hematology 3.1 2015 page 48" href="http://viewer.zmags.com/publication/bc55dcab?page=48"> The first biosimilar was approved in Europe </a> <a title="EMJ Hematology 3.1 2015 page 49" href="http://viewer.zmags.com/publication/bc55dcab?page=49"> Structure (glycol structure)/ function (ADCC) rel</a> <a title="EMJ Hematology 3.1 2015 page 50" href="http://viewer.zmags.com/publication/bc55dcab?page=50"> the same as the reference product and whos</a> <a title="EMJ Hematology 3.1 2015 page 51" href="http://viewer.zmags.com/publication/bc55dcab?page=51"> Approvals for new therapies and combinations </a> <a title="EMJ Hematology 3.1 2015 page 52" href="http://viewer.zmags.com/publication/bc55dcab?page=52"> regulatory approval in 40 of the Lymphoma C</a> <a title="EMJ Hematology 3.1 2015 page 53" href="http://viewer.zmags.com/publication/bc55dcab?page=53"> Med. 2015;372(25):2380-2. 11. ZI AVD. 2015. Avail</a> <a title="EMJ Hematology 3.1 2015 page 54" href="http://viewer.zmags.com/publication/bc55dcab?page=54"> PERSPECTIVES ON THE TREATMENT OF MANTLE CELL</a> <a title="EMJ Hematology 3.1 2015 page 55" href="http://viewer.zmags.com/publication/bc55dcab?page=55"> Session 1: Managing Patients with Relapse</a> <a title="EMJ Hematology 3.1 2015 page 56" href="http://viewer.zmags.com/publication/bc55dcab?page=56"> pathways has enabled the development of tools a</a> <a title="EMJ Hematology 3.1 2015 page 57" href="http://viewer.zmags.com/publication/bc55dcab?page=57"> Emerging Tools for Driving Mantle Cell </a> <a title="EMJ Hematology 3.1 2015 page 58" href="http://viewer.zmags.com/publication/bc55dcab?page=58"> treatment success via MRD and FDG-PET could show </a> <a title="EMJ Hematology 3.1 2015 page 59" href="http://viewer.zmags.com/publication/bc55dcab?page=59"> Closing Remarks for the MCL Session </a> <a title="EMJ Hematology 3.1 2015 page 60" href="http://viewer.zmags.com/publication/bc55dcab?page=60"> course rather than biological and genetic r</a> <a title="EMJ Hematology 3.1 2015 page 61" href="http://viewer.zmags.com/publication/bc55dcab?page=61"> understood.75-77 However, there are stand</a> <a title="EMJ Hematology 3.1 2015 page 62" href="http://viewer.zmags.com/publication/bc55dcab?page=62"> Closing Remarks for the Follicular </a> <a title="EMJ Hematology 3.1 2015 page 63" href="http://viewer.zmags.com/publication/bc55dcab?page=63"> refractory mantle cell lymphoma: a phase 2 study.</a> <a title="EMJ Hematology 3.1 2015 page 64" href="http://viewer.zmags.com/publication/bc55dcab?page=64"> fludarabine, cyclophosphamide, and rituximab</a> <a title="EMJ Hematology 3.1 2015 page 65" href="http://viewer.zmags.com/publication/bc55dcab?page=65"> SUBSCRIBE Follow us: FREE TO OUR YOUTUBE CHA</a> <a title="EMJ Hematology 3.1 2015 page 66" href="http://viewer.zmags.com/publication/bc55dcab?page=66"> ABSTRACT REVIEWS SYNOPSIS OF CLINICALLY ACTION</a> <a title="EMJ Hematology 3.1 2015 page 67" href="http://viewer.zmags.com/publication/bc55dcab?page=67"> EHA which activate the tyrosine kinase or JAK/ST</a> <a title="EMJ Hematology 3.1 2015 page 68" href="http://viewer.zmags.com/publication/bc55dcab?page=68"> ABSTRACT REVIEWS The incorporation of novel targ</a> <a title="EMJ Hematology 3.1 2015 page 69" href="http://viewer.zmags.com/publication/bc55dcab?page=69"> EHA these agents will not work in IBR-failing pa</a> <a title="EMJ Hematology 3.1 2015 page 70" href="http://viewer.zmags.com/publication/bc55dcab?page=70"> ABSTRACT REVIEWS be directly transferred into</a> <a title="EMJ Hematology 3.1 2015 page 71" href="http://viewer.zmags.com/publication/bc55dcab?page=71"> EHA proteolytic cleavage of FXI, FV, FVIII, and </a> <a title="EMJ Hematology 3.1 2015 page 72" href="http://viewer.zmags.com/publication/bc55dcab?page=72"> ABSTRACT REVIEWS 1967;216(5118):857-8. 5. Vu TK </a> <a title="EMJ Hematology 3.1 2015 page 73" href="http://viewer.zmags.com/publication/bc55dcab?page=73"> EHA induced shock, with significantly lower throm</a> <a title="EMJ Hematology 3.1 2015 page 74" href="http://viewer.zmags.com/publication/bc55dcab?page=74"> ABSTRACT REVIEWS also relies on the motility of </a> <a title="EMJ Hematology 3.1 2015 page 75" href="http://viewer.zmags.com/publication/bc55dcab?page=75"> EHA hepatocellular cancer, and gastrointestinal </a> <a title="EMJ Hematology 3.1 2015 page 76" href="http://viewer.zmags.com/publication/bc55dcab?page=76"> RELAPSED/REFRACTORY MULTIPLE MYELOMA: </a> <a title="EMJ Hematology 3.1 2015 page 77" href="http://viewer.zmags.com/publication/bc55dcab?page=77"> disease, at which point the median event-fr</a> <a title="EMJ Hematology 3.1 2015 page 78" href="http://viewer.zmags.com/publication/bc55dcab?page=78"> control arm in a number of ongoing Phase </a> <a title="EMJ Hematology 3.1 2015 page 79" href="http://viewer.zmags.com/publication/bc55dcab?page=79"> Table 1 continued. Drug Study Patient group </a> <a title="EMJ Hematology 3.1 2015 page 80" href="http://viewer.zmags.com/publication/bc55dcab?page=80"> Pomalidomide (POM) is a second-generation</a> <a title="EMJ Hematology 3.1 2015 page 81" href="http://viewer.zmags.com/publication/bc55dcab?page=81"> Young patient; ‘standard’ treatment at prese</a> <a title="EMJ Hematology 3.1 2015 page 82" href="http://viewer.zmags.com/publication/bc55dcab?page=82"> PACE regimen (BOR with DEX, THD, and a 4-day cont</a> <a title="EMJ Hematology 3.1 2015 page 83" href="http://viewer.zmags.com/publication/bc55dcab?page=83"> remains incurable; relapse is all but inevitable,</a> <a title="EMJ Hematology 3.1 2015 page 84" href="http://viewer.zmags.com/publication/bc55dcab?page=84"> inhibitors, the mAbs Elo and DARA, and signal tra</a> <a title="EMJ Hematology 3.1 2015 page 85" href="http://viewer.zmags.com/publication/bc55dcab?page=85"> 25. Jakubowiak AJ et al. Phase I trial of anti-CS</a> <a title="EMJ Hematology 3.1 2015 page 86" href="http://viewer.zmags.com/publication/bc55dcab?page=86"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Hematology 3.1 2015 page 87" href="http://viewer.zmags.com/publication/bc55dcab?page=87"> Buyer’s Guide • ABBVIE • ADAPTIVE BIOTECHNOL</a> <a title="EMJ Hematology 3.1 2015 page 88" href="http://viewer.zmags.com/publication/bc55dcab?page=88"> SUBSCRIBE TO RECEIVE THE LATEST CATIONS, PUBL</a>